# Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

> **NCT00176475** · PHASE1 · TERMINATED · sponsor: **University of Medicine and Dentistry of New Jersey** · enrollment: 2 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** rituximab
- **BIOLOGICAL:** therapeutic allogeneic lymphocytes

## Key facts

- **NCT ID:** NCT00176475
- **Lead sponsor:** University of Medicine and Dentistry of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-01
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2013-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00176475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00176475, "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00176475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*